Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bio-Rad Laboratories (BIO) Receives a Buy from RBC Capital

Tipranks - Tipranks - Wed Jul 2, 2025

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) today and set a price target of $387.00. The company’s shares opened today at $241.43.

Don’t Miss TipRanks’ Half-Year Sale

McNamara covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Illumina, and Repligen. According to TipRanks, McNamara has an average return of -19.9% and a 22.39% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bio-Rad Laboratories with a $321.50 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Bio-Rad Laboratories’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $585.4 million and a net profit of $64 thousand. In comparison, last year the company earned a revenue of $610.82 million and had a net profit of $383.92 million

Read More on BIO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).